Merck & Co. announced that the European Commission approved KEYTRUDA® (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, for the treatment of adults with platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumors express PD‑L1 with a Combined Positive Score (CPS) of 1 or higher and who have received one or two prior systemic therapies.
The approval is backed by the Phase 3 KEYNOTE‑B96 trial, which showed a 28 % reduction in the risk of disease progression or death and a 24 % reduction in the risk of death in the PD‑L1‑positive population (CPS ≥ 1). These clinical benefits establish the combination as the first PD‑1 inhibitor‑based therapy for this patient group in the European Union.
Strategically, the approval expands Merck’s oncology portfolio into a niche, high‑margin indication and positions the company to capture a share of a market with limited treatment options. The addition of the subcutaneous formulation (KEYTRUDA SC®/KEYTRUDA QLEXTM) further supports lifecycle management by extending commercial life and protecting against biosimilar competition.
Management highlighted the significance of the milestone, noting that the new therapy “provides a crucial new treatment option and represents a welcome addition to the treatment landscape for appropriate patients with PD‑L1‑positive platinum‑resistant ovarian cancer across Europe.”
The approval follows a U.S. FDA clearance of the same regimen in February 2026 and comes amid a competitive landscape that includes PARP inhibitors from AstraZeneca and antibody‑drug conjugates from AbbVie. The unmet need for effective therapies in platinum‑resistant ovarian cancer underscores the commercial potential of the new indication.
Sentiment rating: +6
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.